For IL-1β inhibitors that have been approved for clinical use like Canakinumab and Rilonacept, they are originally used to treat auto-inflammatory diseases like Familial Cold Auto-inflammatory Syndrome (CAPS) and gout. Here, IL1B is linked to gout.